DDInter1534 DDInter1376
An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Propafenone {u} (Compound) resembles {v} (Compound) Atomoxetine
Propafenone {u} (Compound) resembles {v} (Compound) Benazepril
Propafenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Salmeterol
Propafenone {u} (Compound) binds {v} (Gene) CYP2C9
Propafenone {u} (Compound) upregulates {v} (Gene) KIAA0355
Propafenone {u} (Compound) downregulates {v} (Gene) IFRD2
Propafenone {u} (Compound) causes {v} (Side Effect) Lupus-like syndrome
Propafenone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Lidocaine
Propafenone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Propafenone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Olodaterol
Propafenone (Compound) resembles Atomoxetine (Compound)
Propafenone (Compound) resembles Benazepril (Compound)
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol
Propafenone (Compound) binds CYP2C9 (Gene)
Propafenone (Compound) upregulates KIAA0355 (Gene)
Propafenone (Compound) downregulates IFRD2 (Gene)
Propafenone (Compound) causes Lupus-like syndrome (Side Effect)
Propafenone may cause a minor interaction that can limit clinical effects when taken with Lidocaine
Propafenone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol